Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018.
While national authorities recommended and provided reimbursement for men who have sex with men under 27 in 2016 and 2017, respectively, we aimed to comprehensively analyze human papillomavirus (HPV) vaccine uptake in French men over a 4-year period surrounding these changes. Data regarding HPV vacc...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2020.1756151 |
| _version_ | 1827809570036121600 |
|---|---|
| author | Jean-David Zeitoun Antoine Duclos Vincent de Parades Jérémie H. Lefèvre |
| author_facet | Jean-David Zeitoun Antoine Duclos Vincent de Parades Jérémie H. Lefèvre |
| author_sort | Jean-David Zeitoun |
| collection | DOAJ |
| description | While national authorities recommended and provided reimbursement for men who have sex with men under 27 in 2016 and 2017, respectively, we aimed to comprehensively analyze human papillomavirus (HPV) vaccine uptake in French men over a 4-year period surrounding these changes. Data regarding HPV vaccine sales to men in all French pharmacies from 2015 through 2018 were retrieved through query made to the national public insurance database. Data were classified according to the age of patients and the time of dispensation so as to display aggregate uptake according to age over time. Time-series analysis was conducted and an exponential smoothing extrapolation was selected to analyze the impact of the reimbursement. Overall, 12,814 HPV vaccines were dispensed in men over the study period. Age was available for the majority of cases (12,793; 99.8%), averaging 29. Dispensation data for each year were the following: 1,917 (2015), 1,921 (2016), 2,643 (2017), 6,312 (2018). Age analysis showed that vaccine uptake among men over 26 was substantial (n = 5974; 46.7%). The exponential increase in the number of vaccines sold started after the second quarter of 2017. In conclusion, we found that HPV vaccine uptake among French men is partly misaligned with recommendations and reimbursement in terms of age, and still moderate overall even though we found signs of marked increase in uptake over the most recent period, suggesting an effective impact of insurance coverage. |
| first_indexed | 2024-03-11T22:42:52Z |
| format | Article |
| id | doaj.art-fcc382adf375482081969883c0f2aaf0 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:42:52Z |
| publishDate | 2020-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-fcc382adf375482081969883c0f2aaf02023-09-22T08:51:48ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2020-12-0116123119312210.1080/21645515.2020.17561511756151Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018.Jean-David Zeitoun0Antoine Duclos1Vincent de Parades2Jérémie H. Lefèvre3Saint-Antoine HospitalLyon University HospitalInstitut Léopold Bellan, Groupe Hospitalier Saint-JosephSorbonne UniversitéWhile national authorities recommended and provided reimbursement for men who have sex with men under 27 in 2016 and 2017, respectively, we aimed to comprehensively analyze human papillomavirus (HPV) vaccine uptake in French men over a 4-year period surrounding these changes. Data regarding HPV vaccine sales to men in all French pharmacies from 2015 through 2018 were retrieved through query made to the national public insurance database. Data were classified according to the age of patients and the time of dispensation so as to display aggregate uptake according to age over time. Time-series analysis was conducted and an exponential smoothing extrapolation was selected to analyze the impact of the reimbursement. Overall, 12,814 HPV vaccines were dispensed in men over the study period. Age was available for the majority of cases (12,793; 99.8%), averaging 29. Dispensation data for each year were the following: 1,917 (2015), 1,921 (2016), 2,643 (2017), 6,312 (2018). Age analysis showed that vaccine uptake among men over 26 was substantial (n = 5974; 46.7%). The exponential increase in the number of vaccines sold started after the second quarter of 2017. In conclusion, we found that HPV vaccine uptake among French men is partly misaligned with recommendations and reimbursement in terms of age, and still moderate overall even though we found signs of marked increase in uptake over the most recent period, suggesting an effective impact of insurance coverage.http://dx.doi.org/10.1080/21645515.2020.1756151msmhpvvaccinerecommendationsreimbursement |
| spellingShingle | Jean-David Zeitoun Antoine Duclos Vincent de Parades Jérémie H. Lefèvre Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. Human Vaccines & Immunotherapeutics msm hpv vaccine recommendations reimbursement |
| title | Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. |
| title_full | Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. |
| title_fullStr | Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. |
| title_full_unstemmed | Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. |
| title_short | Human papillomavirus vaccine uptake among men in France: a national time series analysis for 2015-2018. |
| title_sort | human papillomavirus vaccine uptake among men in france a national time series analysis for 2015 2018 |
| topic | msm hpv vaccine recommendations reimbursement |
| url | http://dx.doi.org/10.1080/21645515.2020.1756151 |
| work_keys_str_mv | AT jeandavidzeitoun humanpapillomavirusvaccineuptakeamongmeninfranceanationaltimeseriesanalysisfor20152018 AT antoineduclos humanpapillomavirusvaccineuptakeamongmeninfranceanationaltimeseriesanalysisfor20152018 AT vincentdeparades humanpapillomavirusvaccineuptakeamongmeninfranceanationaltimeseriesanalysisfor20152018 AT jeremiehlefevre humanpapillomavirusvaccineuptakeamongmeninfranceanationaltimeseriesanalysisfor20152018 |